Aurinia Pharmaceuticals

115 articles with Aurinia Pharmaceuticals

• Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  3/6/2023

  Aurinia Pharmaceuticals Inc. announced that the Company’s Compensation Committee granted 3 new employees inducement stock options to purchase an aggregate of 89,830 common shares.

• Aurinia Reports Fourth Quarter and Full Year 2022 Financial Results and Company Updates

  2/28/2023

  Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for the fourth quarter and the full year ended December 31, 2022.

• Aurinia Pharmaceuticals to Present at Upcoming Investor Healthcare Conference

  2/24/2023

  Aurinia Pharmaceuticals Inc. today announced that Peter Greenleaf, President and Chief Executive Officer, will give a corporate presentation at the upcoming investor healthcare conference.

• Aurinia Pharmaceuticals to Release Fourth Quarter and Full Year Financial and Operational Results on February 28, 2023

  2/7/2023

  Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for fourth quarter and full year 2023 on Tuesday, February 28, 2023, before markets open.

• Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 06, 2023

  2/6/2023

  Aurinia Pharmaceuticals Inc. announced that the Company’s Compensation Committee granted 7 new employees inducement stock options to purchase an aggregate of 70,070 common shares, at a per share exercise price of $9.05, the closing price of Aurinia's common stock on February 3, 2023, and an aggregate of 43,160 inducement restricted stock units.

• Aurinia Announces PTAB Has Terminated Inter Partes Review

  1/25/2023

  Aurinia Pharmaceuticals Inc. announces that the Patent Trial and Appeal Board of the United States’ Patent and Trademark Office has terminated the Inter Partes Review it had instituted with respect to Aurinia’s U.S. Patent No. 10,286,036.

• Aurinia Pharmaceuticals Announces Allowance of a New and Refined Method of Use Patent for LUPKYNIS® in the Treatment of Lupus Nephritis From the United States Patent and Trademark Office

  1/24/2023

  Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the United States Patent and Trademark Office (USPTO) has allowed a method of use patent application titled IMPROVED PROTOCOL FOR TREATMENT OF LUPUS NEPHRITIS.

• Aurinia Provides Preliminary Unaudited Fourth Quarter and Full-year 2022 Net Revenue Results

  1/6/2023

  Aurinia Pharmaceuticals Inc. provided an update on its business performance.

• Aurinia Pharmaceuticals to Present at Upcoming 41st Annual J.P. Morgan Healthcare Conference

  1/4/2023

  Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that Peter Greenleaf, President and Chief Executive Officer, is scheduled to present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11th at 4:30 p.m. Pacific Time / 7:30 p.m. Eastern Time in San Francisco, CA.

• 

  Aurinia and Sun Pharma File Joint Motion to Settle Patent Dispute

  1/3/2023

  Aurinia and Sun Pharma agree to file a joint motion to dismiss a key patent dispute.

• Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 03, 2023

  1/3/2023

  Aurinia Pharmaceuticals Inc. announced that the Company’s Compensation Committee granted 2 new employees inducement stock options to purchase an aggregate of 12,650 common shares, at a per share exercise price of $5.94, the closing price of Aurinia's common stock on January 3, 2023, and an aggregate of 7,730 inducement restricted stock units.

• Aurinia Announces LUPKYNIS® (voclosporin) Patent Challenge Settlement Reached With Sun Pharmaceuticals

  1/3/2023

  Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) announces it has entered into a settlement agreement with Sun Pharmaceutical Industries, Inc., Sun Pharmaceuticals Industries, Ltd., and Sun Pharma Global FZE (collectively, Sun Pharmaceuticals) that involves both Aurinia and Sun Pharmaceuticals filing a joint motion to terminate the ongoing Inter Partes Review (IPR) directed at Aurinia’s U.S. Patent No. 10,286,036.

• Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 05, 2022

  12/5/2022

  Aurinia Pharmaceuticals Inc. announced that the Company’s Compensation Committee granted 2 new employees inducement stock options to purchase an aggregate of 36,220 common shares, at a per share exercise price of $5.10, the closing price of Aurinia's common stock on December 2, 2022, and an aggregate of 22,120 inducement restricted stock units.

• Aurinia Announces the Great Britain Marketing Authorization of LUPKYNIS® (voclosporin) for the Treatment of Lupus Nephritis

  11/30/2022

  Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company) announced that the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) has granted the Great Britain marketing authorization of LUPKYNIS® (voclosporin) to treat adults with active lupus nephritis (LN), a serious complication of systemic lupus erythematosus (SLE).

• Aurinia Reports Third Quarter and Nine Months 2022 Financial and Operational Results

  11/3/2022

  Aurinia Pharmaceuticals Inc. issued its financial results for the three months ended September 30, 2022. Amounts, unless specified otherwise, are expressed in U.S. dollars.

• Aurinia Pharmaceuticals to Release Third Quarter 2022 Financial and Operational Results on November 3, 2022

  10/28/2022

  Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for third quarter 2022 on Thursday, November 3, 2022, before markets open.

• Aurinia Pharmaceuticals Announces Presentations at American Society of Nephrology (ASN) Kidney Week 2022

  10/27/2022

  Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company) today announced that data from multiple studies of LUPKYNIS® (voclosporin) will be presented at the American Society of Nephrology (ASN) Kidney Week 2022, taking place November 3-6 in Orlando, Florida.

• Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 03, 2022

  10/3/2022

  Aurinia Pharmaceuticals Inc. announced that the Company’s Compensation Committee granted 4 new employees inducement stock options to purchase an aggregate of 20,800 common shares, at a per share exercise price of $7.52, the closing price of Aurinia's common stock on September 30, 2022, and an aggregate of 12,500 inducement restricted stock units.

• Aurinia Pharmaceuticals Announces Presentations at American College of Rheumatology (ACR) Convergence 2022

  9/20/2022

  Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company) today announced that data from multiple studies of LUPKYNIS® (voclosporin), used to treat adults with active lupus nephritis (LN), a serious complication of systemic lupus erythematosus (SLE), will be presented at American College of Rheumatology (ACR) Convergence 2022.

• Aurinia Announces European Commission Approval of LUPKYNIS® (voclosporin) for the Treatment of Lupus Nephritis

  9/19/2022

  Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the trajectory of autoimmune disease, announced that the European Commission (EC) has granted marketing authorization of LUPKYNIS® (voclosporin) to treat adults with active lupus nephritis (LN), a serious complication of systemic lupus erythematosus (SLE).